289 related articles for article (PubMed ID: 30963667)
1. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.
Bock P; Nel K; Fatti G; Sloot R; Ford N; Voget J; Gunst C; Grobbelaar N; Louis F; Floyd S; Hayes R; Ayles H; Beyers N; Fidler S;
HIV Med; 2019 Jul; 20(6):392-403. PubMed ID: 30963667
[TBL] [Abstract][Full Text] [Related]
2. Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa.
Bock P; Fatti G; Ford N; Jennings K; Kruger J; Gunst C; Louis F; Grobbelaar N; Shanaube K; Floyd S; Grimwood A; Hayes R; Ayles H; Fidler S; Beyers N;
PLoS One; 2018; 13(4):e0195127. PubMed ID: 29672542
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa.
Bock P; Jennings K; Vermaak R; Cox H; Meintjes G; Fatti G; Kruger J; De Azevedo V; Maschilla L; Louis F; Gunst C; Grobbelaar N; Dunbar R; Limbada M; Floyd S; Grimwood A; Ayles H; Hayes R; Fidler S; Beyers N
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):93-101. PubMed ID: 29016524
[TBL] [Abstract][Full Text] [Related]
4. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.
De Waal R; Cohen K; Fox MP; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
J Int AIDS Soc; 2017 Apr; 20(1):21317. PubMed ID: 28406595
[TBL] [Abstract][Full Text] [Related]
5. Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa.
Fatti G; Grimwood A; Nachega JB; Nelson JA; LaSorda K; van Zyl G; Grobbelaar N; Ayles H; Hayes R; Beyers N; Fidler S; Bock P
Clin Infect Dis; 2020 Jan; 70(3):395-403. PubMed ID: 30877753
[TBL] [Abstract][Full Text] [Related]
6. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study.
Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C
PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014
[TBL] [Abstract][Full Text] [Related]
7. Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Achhra AC; Mocroft A; Ross MJ; Ryom L; Lucas GM; Furrer H; Neuhaus J; Somboonwit C; Kelly M; Gatell JM; Wyatt CM;
HIV Med; 2015 Apr; 16 Suppl 1(0 1):55-63. PubMed ID: 25711324
[TBL] [Abstract][Full Text] [Related]
8. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.
Nakanjako D; Kiragga AN; Musick BS; Yiannoutsos CT; Wools-Kaloustian K; Diero L; Oyaro P; Lugina E; Ssali JC; Kambugu A; Easterbrook P
AIDS; 2016 Jul; 30(12):1913-22. PubMed ID: 26959510
[TBL] [Abstract][Full Text] [Related]
9. Renal dysfunction among adult HIV/AIDS patients on antiretroviral therapy at a tertiary facility in Ghana.
Obiri-Yeboah D; Awuku YA; Alofa W; Charwudzi A; Aniakwa-Bonsu E; Obboh E; Nsiah P
BMC Nephrol; 2018 Nov; 19(1):333. PubMed ID: 30463531
[TBL] [Abstract][Full Text] [Related]
10. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
[TBL] [Abstract][Full Text] [Related]
11. CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: An analysis of national laboratory based data.
Kufa T; Shubber Z; MacLeod W; Takuva S; Carmona S; Bor J; Gorgens M; Pillay Y; Puren A; Eaton JW; Fraser-Hurt N
PLoS One; 2019; 14(5):e0217742. PubMed ID: 31150489
[TBL] [Abstract][Full Text] [Related]
12. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
Reid A; Stöhr W; Walker AS; Williams IG; Kityo C; Hughes P; Kambugu A; Gilks CF; Mugyenyi P; Munderi P; Hakim J; Gibb DM;
Clin Infect Dis; 2008 Apr; 46(8):1271-81. PubMed ID: 18444867
[TBL] [Abstract][Full Text] [Related]
13. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
[TBL] [Abstract][Full Text] [Related]
14. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
[TBL] [Abstract][Full Text] [Related]
16. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.
Nash D; Wu Y; Elul B; Hoos D; El Sadr W;
AIDS; 2011 Jul; 25(12):1523-33. PubMed ID: 21750418
[TBL] [Abstract][Full Text] [Related]
17. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Stöhr W; Reid A; Walker AS; Ssali F; Munderi P; Mambule I; Kityo C; Grosskurth H; Gilks CF; Gibb DM; Hakim J;
Antivir Ther; 2011; 16(7):1011-20. PubMed ID: 22024517
[TBL] [Abstract][Full Text] [Related]
18. HIV testing and treatment coverage achieved after 4 years across 14 urban and peri-urban communities in Zambia and South Africa: An analysis of findings from the HPTN 071 (PopART) trial.
Floyd S; Shanaube K; Yang B; Schaap A; Griffith S; Phiri M; Macleod D; Sloot R; Sabapathy K; Bond V; Bock P; Ayles H; Fidler S; Hayes R;
PLoS Med; 2020 Apr; 17(4):e1003067. PubMed ID: 32240156
[TBL] [Abstract][Full Text] [Related]
19. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.
Grimsrud A; Cornell M; Schomaker M; Fox MP; Orrell C; Prozesky H; Stinson K; Tanser F; Egger M; Myer L;
J Epidemiol Community Health; 2016 Jun; 70(6):549-55. PubMed ID: 26700300
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ cell counts.
Worodria W; Ssempijja V; Hanrahan C; Ssegonja R; Muhofwa A; Mazapkwe D; Mayanja-Kizza H; Reynolds SJ; Colebunders R; Manabe YC
AIDS; 2018 Sep; 32(15):2141-2149. PubMed ID: 30005014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
